Adrenal hyperplasia and adenomas are associated with inhibition of phosphodiesterase 11A in carriers of PDE11A sequence variants that are frequent in the population.
about
Molecular genetics of adrenocortical tumor formation and potential pharmacologic targetsAlterations of Phosphodiesterases in Adrenocortical TumorsPhosphodiesterase 11A in brain is enriched in ventral hippocampus and deletion causes psychiatric disease-related phenotypes.Association of the M1V PRKAR1A mutation with primary pigmented nodular adrenocortical disease in two large families.Recurrent activating mutation in PRKACA in cortisol-producing adrenal tumorsCyclic AMP, protein kinase A, and phosphodiesterases: proceedings of an international workshopMutations and polymorphisms in the gene encoding regulatory subunit type 1-alpha of protein kinase A (PRKAR1A): an update.Carney complex and other conditions associated with micronodular adrenal hyperplasias.Frequent phosphodiesterase 11A gene (PDE11A) defects in patients with Carney complex (CNC) caused by PRKAR1A mutations: PDE11A may contribute to adrenal and testicular tumors in CNC as a modifier of the phenotype.Phosphodiesterase 11A (PDE11A) genetic variants may increase susceptibility to prostatic cancer.How does cAMP/protein kinase A signaling lead to tumors in the adrenal cortex and other tissues?Cushing syndrome caused by adrenocortical tumors and hyperplasias (corticotropin- independent Cushing syndrome)Phosphodiesterase 11A (PDE11A) and genetic predisposition to adrenocortical tumorsCarney complex and lentiginosisAbnormalities of cAMP signaling are present in adrenocortical lesions associated with ACTH-independent Cushing syndrome despite the absence of mutations in known genes.Multiple endocrine neoplasias: advances and challenges for the futureDetection of somatic beta-catenin mutations in primary pigmented nodular adrenocortical disease (PPNAD).p54nrb/NONO regulates cyclic AMP-dependent glucocorticoid production by modulating phosphodiesterase mRNA splicing and degradation.Phosphodiesterase sequence variants may predispose to prostate cancer.Activation of cyclic AMP signaling leads to different pathway alterations in lesions of the adrenal cortex caused by germline PRKAR1A defects versus those due to somatic GNAS mutationsIdentification of novel genetic variants in phosphodiesterase 8B (PDE8B), a cAMP-specific phosphodiesterase highly expressed in the adrenal cortex, in a cohort of patients with adrenal tumours.Phosphodiesterase 11A (PDE11A) gene defects in patients with acth-independent macronodular adrenal hyperplasia (AIMAH): functional variants may contribute to genetic susceptibility of bilateral adrenal tumorsAn immortalized human cell line bearing a PRKAR1A-inactivating mutation: effects of overexpression of the wild-type Allele and other protein kinase A subunitsPhosphodiesterase function and endocrine cells: links to human disease and roles in tumor development and treatmentcAMP/PKA signaling defects in tumors: genetics and tissue-specific pluripotential cell-derived lesions in human and mouse.The transcriptome that mediates increased cyclic adenosine monophosphate signaling in PRKAR1A defects and other settings.Operative management of Cushing syndrome secondary to micronodular adrenal hyperplasia.Primary pigmented nodular adrenocortical disease and Cushing's syndrome.Cyclic AMP and c-KIT signaling in familial testicular germ cell tumor predisposition.Unraveling the molecular basis of micronodular adrenal hyperplasia.New genes and/or molecular pathways associated with adrenal hyperplasias and related adrenocortical tumors.A cAMP-specific phosphodiesterase (PDE8B) that is mutated in adrenal hyperplasia is expressed widely in human and mouse tissues: a novel PDE8B isoform in human adrenal cortex.Mutations in regulatory subunit type 1A of cyclic adenosine 5'-monophosphate-dependent protein kinase (PRKAR1A): phenotype analysis in 353 patients and 80 different genotypes.Phosphodiesterase 11A expression in the adrenal cortex, primary pigmented nodular adrenocortical disease, and other corticotropin-independent lesions.Phosphodiesterase genes and antidepressant treatment response: a review.Clinical and genetic heterogeneity, overlap with other tumor syndromes, and atypical glucocorticoid hormone secretion in adrenocorticotropin-independent macronodular adrenal hyperplasia compared with other adrenocortical tumors.Functional phosphodiesterase 11A mutations may modify the risk of familial and bilateral testicular germ cell tumors.Carney complex and McCune Albright syndrome: an overview of clinical manifestations and human molecular genetics.Clinical and molecular genetics of the phosphodiesterases (PDEs).5th International ACC Symposium: The New Genetics of Benign Adrenocortical Neoplasia: Hyperplasias, Adenomas, and Their Implications for Progression into Cancer.
P2860
Q26849995-0C95BE8A-3FE3-4047-9CEB-75523F93B687Q28066278-12ACB43D-6915-4E69-8446-60FA2D5F92A1Q30478804-99D5F4BD-A491-4F0D-ACA2-9069873CC8E8Q33586753-C4DFF50D-F05F-4B66-8DE1-B0AF2AFD2DA1Q33820159-2BF41C1E-730A-44E3-9F39-25154101E65DQ34055579-647E1BDD-BA27-4B01-A9C2-7061F8EF9AB1Q34113281-5CEA4B5C-D0F7-43D4-BC9E-837C9FBF9B52Q34398710-D7B21792-508E-4F8B-819B-8FFE43F52B99Q34571810-D22A744A-2761-470D-9853-DF5AAB642AC9Q34571859-C12A6A51-BA1D-44F8-AAE6-C7D363FDBA24Q34629130-6AF41E75-6130-45F2-90D0-DDBF4E347203Q35095366-0F38210D-DCDE-42EA-A103-BCED9556D844Q35100928-0102F92E-452F-4792-8021-EAE881B66019Q35106673-AD909D7C-E12D-4E13-B49A-AE487B7FA57BQ35106820-FB7EE9EA-44BF-4F1E-BBE8-5B71AE37061CQ35110716-AA959DBD-E96C-4497-BDE3-2AB1618047E5Q35110734-3931C5A6-EFA9-44F6-9B0A-20247169537AQ35165187-6293D9D9-2BC4-463F-B4B9-613B858E7A3EQ35843428-F39D3E35-CE00-4DE5-A799-31B005A8377AQ35869529-BE3785E0-0A20-4C72-9781-3BC87A09C32CQ35990225-EFDF9B52-5514-46CA-8133-4BF3B5C1F4F9Q36361438-E6AE639D-4776-470C-A9A6-C0B0477DFC6CQ36459930-4F6A075F-DD9E-4720-8E79-0DEB55B0DCD4Q36503940-46C25D6B-5934-43D6-997A-9CDBC386D151Q36763148-0F0BC3C9-8951-46D1-A4A2-F2AE304FF4C5Q36838955-7D8C832B-A134-4478-A0CF-9C07EBDCFB6DQ37013013-428B62AC-5756-46C7-B8D3-1C866C79CE4CQ37062040-50DE18F5-8DD7-4999-BA75-45E47E0EE9E9Q37071259-025612FC-F15B-49FC-ADAC-2618DF9C465AQ37148159-D4A8C52D-F7DB-4045-A8B7-36AAD876988AQ37156654-CD022862-8866-4CEB-AB6A-82D71FBCF3B6Q37163859-155B4798-1906-4FCB-8647-50D73151E693Q37212283-27DEA957-9A0E-4CF9-8FB4-AD57C82FEEB8Q37267926-FF6DDB75-DB23-4AD3-9314-999966D0CA18Q37302885-C9F5CDA6-7A81-4678-8CE4-7C5E034A4502Q37315688-C5C655C4-5C17-43C0-9797-C4427F969DA6Q37325191-B832A111-517A-4281-859D-FBDEA9701A50Q37619451-86945264-0BC3-4532-89AF-68C5538235A6Q37657841-9023CF30-3F70-4CF3-BF7E-500518F498E9Q38673938-45EDCE5C-CED2-450C-A8EF-B10920C08291
P2860
Adrenal hyperplasia and adenomas are associated with inhibition of phosphodiesterase 11A in carriers of PDE11A sequence variants that are frequent in the population.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Adrenal hyperplasia and adenom ...... re frequent in the population.
@en
type
label
Adrenal hyperplasia and adenom ...... re frequent in the population.
@en
prefLabel
Adrenal hyperplasia and adenom ...... re frequent in the population.
@en
P2093
P50
P1433
P1476
Adrenal hyperplasia and adenom ...... re frequent in the population.
@en
P2093
Anelia Horvath
Christoforos Giatzakis
Elizabeth Levine
Ioannis Bossis
J Aidan Carney
Kurt Griffin
Sosipatros Boikos
Virginia Kamvissi
P304
11571-11575
P356
10.1158/0008-5472.CAN-06-2914
P407
P50
P577
2006-12-01T00:00:00Z